AFT Pharma unveils record revenues of $115 million on global expansion

AFT Pharma (ASX:AFP) has this week unveiled impressive first calendar half results, with revenues up 33% to just south of $115 million, which has left the company “pretty pleased” and ready for the coming months.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

Disclaimer: This content is disseminated in partnership with AFT Pharmaceuticals Ltd. It is intended to inform investors and should not be taken as a recommendation or financial advice.

AFT Pharma CEO and founder, Hartley Atkinson, joined The Market Link‘s Jonathon Davidson to discuss the news in the latest Watchlist interview.

“We’ve seen some good, solid growth right across the board,” Dr Atkinson told The Market Link. “We’re starting to get greater traction in our global expansion [and today we’re] selling in 85 countries around the globe.”

AFT Pharma’s founder also pointed out home markets had been “very strong as well,” even as the company really drives expansion globally.

You can watch the full AFT Pharma Watchlist interview in the browser above.

Join the discussion. See what HotCopper users are saying about AFT Pharmaceuticals Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.